Chonluten · 20MG

Chonluten is a short-chain peptide bioregulator developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Belonging to the same "Khavinson bioregulator" class as Epithalon, Cortagen, and Pinealon, Chonluten is the tripeptide identified by Khavinson and colleagues as the bronchial / respiratory epithelium peptide bioregulator. The compound consists of the sequence Glu-Asp-Gly (EDG) and is proposed to function through tissue-specific gene expression modulation in respiratory epithelial cell populations. Chonluten has been investigated in the Russian academic literature (Bulletin of Experimental Biology and Medicine; Khavinson, Chalisova, and colleagues) for pulmonary cell biology, bronchial epithelium gene expression, and age-associated respiratory tract function in preclinical research models. Like other Khavinson bioregulators, Chonluten is studied primarily as a research tool for tissue-specific short-peptide pharmacology rather than as a defined receptor agonist.

Benefits (Research Focus)

• Bronchial epithelium pharmacology — studied for short-peptide bioregulator effects on respiratory cell populations

• Pulmonary cell biology — investigated for gene expression modulation in respiratory tract research models

• Khavinson SAR research — explored alongside other Khavinson short-peptide bioregulators for structure-activity studies

• Tissue-specific peptide signaling — examined as a "cytomedin" / cytogen class compound for tissue-selective gene expression research

• Age-associated respiratory research — researched for respiratory cell biology endpoints in aged tissue models

What Researchers Look At

• Bronchial epithelial gene expression and proliferation markers

• Comparative pharmacology versus other Khavinson short-peptide bioregulators

• Tissue-selective peptide uptake and cellular signaling pathways

• Respiratory epithelium model systems (in vitro and ex vivo)

• Age-related changes in bronchial cell biology and peptide response in research models

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 20 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Chonluten

• Synonyms: EDG peptide; Glu-Asp-Gly tripeptide; Khavinson bronchial peptide bioregulator

• Class: Synthetic tripeptide; Khavinson bioregulator / cytomedin class; bronchial epithelium-targeted

• Sequence: Glu-Asp-Gly (EDG) — 3 amino acids

• Origin: Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology (Russia)

• Formula / M.W.: C₁₁H₁₇N₃O₈, ~319.27 g/mol (verify against batch COA)

• CAS: Not formally assigned (peptide bioregulator class)

⚠️ Disclaimer

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Chonluten VPeptide Canada — November 20, 2025